BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 31013001)

  • 21. Evaluation of BRAF, RAS, RET/PTC, and PAX8/PPARg alterations in different Bethesda diagnostic categories: A multicentric prospective study on the validity of the 7-gene panel test in 1172 thyroid FNAs deriving from different hospitals in South Italy.
    Bellevicine C; Migliatico I; Sgariglia R; Nacchio M; Vigliar E; Pisapia P; Iaccarino A; Bruzzese D; Fonderico F; Salvatore D; Biondi B; Masone S; Novizio V; Scavuzzo F; Serino D; De Palma M; Chiofalo MG; Botti G; Pezzullo L; Nuzzo V; Spiezia S; De Chiara G; Iorio S; Conzo G; Docimo G; Faggiano A; Bongiovanni M; Malapelle U; Colao A; Triassi M; Troncone G;
    Cancer Cytopathol; 2020 Feb; 128(2):107-118. PubMed ID: 31821746
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The mutational analysis in the diagnostic work-up of thyroid nodules: the real impact in a center with large experience in thyroid cytopathology.
    Macerola E; Rago T; Proietti A; Basolo F; Vitti P
    J Endocrinol Invest; 2019 Feb; 42(2):157-166. PubMed ID: 29704233
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Malignant risk stratification of thyroid FNA specimens with indeterminate cytology based on molecular testing.
    Paskaš S; Janković J; Živaljević V; Tatić S; Božić V; Nikolić A; Radojković D; Savin S; Cvejić D
    Cancer Cytopathol; 2015 Aug; 123(8):471-9. PubMed ID: 25924719
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Incremental utility of expanded mutation panel when used in combination with microRNA classification in indeterminate thyroid nodules.
    Jackson S; Kumar G; Banizs AB; Toney N; Silverman JF; Narick CM; Finkelstein SD
    Diagn Cytopathol; 2020 Jan; 48(1):43-52. PubMed ID: 31675178
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Performance of a Genomic Sequencing Classifier for the Preoperative Diagnosis of Cytologically Indeterminate Thyroid Nodules.
    Patel KN; Angell TE; Babiarz J; Barth NM; Blevins T; Duh QY; Ghossein RA; Harrell RM; Huang J; Kennedy GC; Kim SY; Kloos RT; LiVolsi VA; Randolph GW; Sadow PM; Shanik MH; Sosa JA; Traweek ST; Walsh PS; Whitney D; Yeh MW; Ladenson PW
    JAMA Surg; 2018 Sep; 153(9):817-824. PubMed ID: 29799911
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Indeterminate Single Thyroid Nodule: Synergistic Impact of Mutational Markers and Sonographic Features in Triaging Patients to Appropriate Surgery.
    De Napoli L; Bakkar S; Ambrosini CE; Materazzi G; Proietti A; Macerola E; Basolo F; Miccoli P
    Thyroid; 2016 Mar; 26(3):390-4. PubMed ID: 26548748
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ACR TI-RADS and ATA US scores are helpful for the management of thyroid nodules with indeterminate cytology.
    Barbosa TLM; Junior COM; Graf H; Cavalvanti T; Trippia MA; da Silveira Ugino RT; de Oliveira GL; Granella VH; de Carvalho GA
    BMC Endocr Disord; 2019 Oct; 19(1):112. PubMed ID: 31664992
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ruling in or ruling out thyroid malignancy by molecular diagnostics of thyroid nodules.
    Eszlinger M; Hegedüs L; Paschke R
    Best Pract Res Clin Endocrinol Metab; 2014 Aug; 28(4):545-57. PubMed ID: 25047205
    [TBL] [Abstract][Full Text] [Related]  

  • 29. BRAF
    Jinih M; Foley N; Osho O; Houlihan L; Toor AA; Khan JZ; Achakzai AA; Redmond HP
    Eur J Surg Oncol; 2017 Jul; 43(7):1219-1227. PubMed ID: 27923591
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular analysis of residual ThinPrep material from thyroid FNAs increases diagnostic sensitivity.
    Krane JF; Cibas ES; Alexander EK; Paschke R; Eszlinger M
    Cancer Cytopathol; 2015 Jun; 123(6):356-61. PubMed ID: 25926393
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular Classification of Thyroid Nodules with Indeterminate Cytology: Development and Validation of a Highly Sensitive and Specific New miRNA-Based Classifier Test Using Fine-Needle Aspiration Smear Slides.
    Santos MTD; Buzolin AL; Gama RR; Silva ECAD; Dufloth RM; Figueiredo DLA; Carvalho AL
    Thyroid; 2018 Dec; 28(12):1618-1626. PubMed ID: 30319072
    [No Abstract]   [Full Text] [Related]  

  • 32. BRAF V600E mutation analysis of thyroid nodules needle aspirates in relation to their ultrasongraphic classification: a potential guide for selection of samples for molecular analysis.
    Nam SY; Han BK; Ko EY; Kang SS; Hahn SY; Hwang JY; Nam MY; Kim JW; Chung JH; Oh YL; Shin JH
    Thyroid; 2010 Mar; 20(3):273-9. PubMed ID: 20187782
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Next-Generation Sequencing Identifies a Highly Accurate miRNA Panel That Distinguishes Well-Differentiated Thyroid Cancer from Benign Thyroid Nodules.
    Mazeh H; Deutch T; Karas A; Bogardus KA; Mizrahi I; Gur-Wahnon D; Ben-Dov IZ
    Cancer Epidemiol Biomarkers Prev; 2018 Aug; 27(8):858-863. PubMed ID: 30049841
    [No Abstract]   [Full Text] [Related]  

  • 34. RET/PTC rearrangements in thyroid nodules: studies in irradiated and not irradiated, malignant and benign thyroid lesions in children and adults.
    Elisei R; Romei C; Vorontsova T; Cosci B; Veremeychik V; Kuchinskaya E; Basolo F; Demidchik EP; Miccoli P; Pinchera A; Pacini F
    J Clin Endocrinol Metab; 2001 Jul; 86(7):3211-6. PubMed ID: 11443191
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Independent Comparison of the Afirma Genomic Sequencing Classifier and Gene Expression Classifier for Cytologically Indeterminate Thyroid Nodules.
    Angell TE; Heller HT; Cibas ES; Barletta JA; Kim MI; Krane JF; Marqusee E
    Thyroid; 2019 May; 29(5):650-656. PubMed ID: 30803388
    [No Abstract]   [Full Text] [Related]  

  • 36. Afirma Gene Sequencing Classifier Compared with Gene Expression Classifier in Indeterminate Thyroid Nodules.
    Endo M; Nabhan F; Porter K; Roll K; Shirley LA; Azaryan I; Tonkovich D; Perlick J; Ryan LE; Khawaja R; Meng S; Phay JE; Ringel MD; Sipos JA
    Thyroid; 2019 Aug; 29(8):1115-1124. PubMed ID: 31154940
    [No Abstract]   [Full Text] [Related]  

  • 37. miRNA expression can classify pediatric thyroid lesions and increases the diagnostic yield of mutation testing.
    Franco AT; Labourier E; Ablordeppey KK; Surrey LF; Mostoufi-Moab S; Isaza A; Adzick NS; Kazahaya K; Kumar G; Bauer AJ
    Pediatr Blood Cancer; 2020 Jun; 67(6):e28276. PubMed ID: 32196952
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hurthle cell predominance impacts results of Afirma gene expression classifier and ThyroSeq molecular panel performance in indeterminate thyroid nodules.
    Parajuli S; Jug R; Ahmadi S; Jiang XS
    Diagn Cytopathol; 2019 Nov; 47(11):1177-1183. PubMed ID: 31348619
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Performance of the Afirma Gene Expression Classifier in Hürthle Cell Thyroid Nodules Differs from Other Indeterminate Thyroid Nodules.
    Brauner E; Holmes BJ; Krane JF; Nishino M; Zurakowski D; Hennessey JV; Faquin WC; Parangi S
    Thyroid; 2015 Jul; 25(7):789-96. PubMed ID: 25962906
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of Gene Expression Classifier Molecular Testing on the Surgical Decision-Making Process for Patients With Thyroid Nodules.
    Noureldine SI; Olson MT; Agrawal N; Prescott JD; Zeiger MA; Tufano RP
    JAMA Otolaryngol Head Neck Surg; 2015 Dec; 141(12):1082-8. PubMed ID: 26606459
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.